Contents:

1. The Drug Delivery System Market and Business 1.1 Key Findings 1.2 Current and Future DDS Market and Business Potential 1.2.1 More Growth Expected in Next Few Years 1.2.2 The Pharmaceutical Industry is Facing a Productivity Gap 1.2.3 Profitable Drugs To Lose Patent Protection and Market Exclusivity 1.2.4 Using Patent Extension Strategies for Product Life-Cycle Management 1.3 Partnership Strategy 1.3.1 New Drugs Continue to Hit the Market in Near Term 1.3.2 Big Pharmas Cannot Work Alone to Make Drugs 1.4 Technology Exposure 1.4.1 Commercial Interests 1.4.2 Post-Genomic Advances 1.4.3 Emerging Targeted Therapies 1.4.4 Large Molecule Biopharmaceuticals: Protein and Peptide Drugs 1.4.5 More Knowledge About Disease Mechanisms 1.5 Drivers and Resistors to DDS Reformulation 1.5.1 Market is Fragmented 1.5.2 The Field Continues To Expand 1.6 Strategic Analysis of key DDS Players 1.6.1 Drug Delivery Technologies Preferred by the Pharma Industry 1.6.2 Drug Delivery Business Models Continue Shift to Products 2. Key Drug Delivery Technology & Reformulation and Roadmap 2.1 Key Technology Findings 2.2 Oral Drug Delivery 2.3 Bone Marrow Infusion 2.3.2 Delivery of Drugs into Bone Marrow 2.3.3 Delivery of Bone Marrow-based Stem Cells 2.3.4 Delivery of Other Cell Therapies to Bone Marrow 2.4 Injectable Drug Delivery (Parenteral) 2.5 Transdermal Drug Delivery 2.6 Transmucosal Drug Delivery 2.7 Organ System Specific Drug Delivery 2.7.1 Genito-Urinary Tract (GU) 2.7.2 Nasal Delivery to Central Nervous System (CNS) 2.7.3 Cardiovascular System (CV) 2.7.4 Ocular Drug Delivery 2.7.5 Pulmonary Drug Delivery 2.7.6 Stomach & Gastrointestinal Tract (GI) 2.8 Controlled Release Systems 2.9 Novel Packaging and Formulations 2.9.1 Orally Disintegrating Tablets (Fast Dissolving) 2.9.2 Chewable Tablets 2.9.3 Solubility and Bioavailability Enhancement 2.10 Highly Targeted Drug Delivery 2.10.1 Polymer and Collagen Systems 2.10.2 Particle-Based Systems 2.10.2.1 Therapeutic Monoclonal Antibodies. 2.10.2.2 Liposomes 2.10.2.3 Microparticles 2.10.2.4 Modified Blood Cells 2.10.2.5 Nanoparticles 2.10.2.6 Viral Assisted Intracellular Gene Delivery 2.10.2.7 Non-Viral Intracellular Gene Delivery 3. Strategic Alliances and M&As 3.1 Traditional Drug Delivery Licensing Business Model 3.2 Drug Product Based Drug Delivery Business Model 3.3 Driving the Need to Partner 3.4 Alliance Analysis, 2003 to mid-2005 4. Emerging Technology for Drug Delivery 4.1 Analysis of Emerging Drug Delivery Technologies 4.2 Nano Drug Delivery 4.3 Protein Drug Delivery 4.4 Polymer Development 4.5 Therapeutic Monoclonal Antibody Development 4.6 PEGnology Development 4.7 Inhalation System Development 4.8 Buccal Delivery Development 4.9 Ocular Delivery Development 4.10 Vaccine Delivery Development 4.11 Other Emerging Technology 5. Market Forecast and Future Outlook 5.1 US Drug Delivery Market Trends 5.1.1 A Strong Market 5.1.2 Solutions for Unmet Medical Needs 5.1.3 Doctors and Patients Prefer No Pain 5.1.4 Drug Delivery Helps Pharmaceutical Firms to Compete 5.2 US Drug Delivery Market Size by Segment 2004-2009 5.2.1 Market Segments 5.2.2 Oral Drug Delivery 5.2.3 Parenteral Drug Delivery 5.2.4 Injection Devices 5.2.5 Inhaled Drug Delivery 5.2.6 Inhaler Devices (Nebulizer, Spacers) 5.2.7 Transdermal Drug Delivery 5.2.8 Implant Drug Delivery 5.2.9 Transmucosal Drug Delivery 5.2.10 Therapeutic Antibodies 5.2.11 Therapeutic & Cancer Vaccines 5.2.12 Gene Therapy/Delivery 5.2.13 Other Drug Delivery 5.3 Market Shares of the US Drug Delivery Market, 2004 and 2009 5.4 Platforms/ Products in the Competitive Vendor Landscape 6. Selected Legal Disputes 6.1 IVAX, Teva Pharmaceutical Industries Ltd., et al v. Eli Lilly 6.2 Johnson & Johnson v. Boston Scientific 6.3 Chiron Corporation v. Corus Pharma, Inc. 6.4 Novartis Pharmaceuticals Corp., et al v. Sun Pharmaceutical Industries Ltd. 6.5 GlaxoSmithKline Plc v. Par Pharmaceutical Companies, Inc. 6.6 Santarus, Inc. v. TAP Pharmaceutical Products, Inc. 6.7 Travanti Pharma Inc. v. IOMED 7. Activities of Leading Drug Delivery Firms Common Research Items Company Profile - Contact - Established Year - Revenue - # of Employees Company Overview, Technology & Products Alliances, Mergers and Acquisitions Other Finding 7.1 DNA/RNA Delivery(4) 7.2 Multiple Delivery Platform(4) 7.3 Nasal/Lung Delivery(3) 7.4 Other Drug Delivery(3) 7.5 Particle Drug Delivery(3) 7.6 Speciality Pharma(2) 7.7 Therapeutic MAb Delivery(2) 7.8 Transdermal/Transmucosal Delivery(4) 8. The Top 50 Drug Delivery Companies 9. Appendix A: Links to Drug Delivery Websites 9.1 Pharmaceutical and Biotechnology Industry Sites 9.2 Government Regulatory Agencies 9.3 Pharmaceutical Industry News Sites 10. Appendix B: Glossary of Drug Delivery Terms LIST OF TABLES Table 1. US Drug Delivery Systems (DDS) Market Size, 2004-2009 Table 2. Analysis of Alliances, Mergers and Acquisitions of DDS Companies Table 3. Selected Drug Delivery Company Alliances in 2005/ (First Half) Table 4. Selected Drug Delivery Company Alliances in 2004 Table 5. Selected Drug Delivery Company Alliances in 2003 Table 6. Emerging Drug Delivery Technologies Table 7. US Drug Delivery Market Size, Revenues by Segments, 2004-2009 Table 8. US DDS Market Revenues by Share, 2004 and 2009 Table 9. Leading Drug Delivery Companies Mapped by Competing Platforms/Products Table 10. Legal Disputes Among Selected Companies Involving Drug Delivery Table 11. The Top 50 WW Drug Delivery Companies by Total Revenues (2004 $M) LIST OF ILLUSTRATIONS Figure 1. US Drug Delivery Systems (DDS) Market Size, 2004-2009 Figure 2. The GI Tract and Oral Drug Delivery Route (by Mouth) Figure 3. Intraosseous (Bone Marrow) Infusion Figure 4. Injection Based Drug Delivery Methods Figure 5. Transdermal Patch Drug Delivery Figure 6. 3M's Multi-layer Drug-in-Adhesive Transdermal Patch Figure 7. Johnson & Johnson's Drug-Coated Stent Figure 8. Pulmonary Delivery Solutions Figure 9. Penwest's TIMERx(r) Drug Delivery Technology Figure 10. US Drug Delivery Market Size, Revenues by Segment, 2004-2009 Figure 11. US DDS Market Revenues by Share, 2004 and 2009